Published in Oncotarget on October 25, 2016
STATs and gene regulation. Science (1997) 16.55
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature (1998) 5.04
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res (2010) 1.91
Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun (2005) 1.76
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia (2010) 1.70
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem (2012) 1.39
STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol (2012) 1.36
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal Biochem (2004) 1.32
Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem (2012) 1.25
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett (2010) 1.23
A new small-molecule Stat3 inhibitor. Chem Biol (2006) 1.20
STAT3 the oncogene - still eluding therapy? FEBS J (2015) 1.20
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) (2014) 1.17
Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun (2008) 1.11
A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res (2013) 1.09
Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol (2009) 1.09
A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem Biol (2014) 1.08
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett (2014) 1.08
Progress towards the development of SH2 domain inhibitors. Chem Soc Rev (2013) 1.05
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer (2012) 0.99
Regulation of STAT signaling by acetylation. Cell Signal (2013) 0.99
Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography. FEBS Lett (2013) 0.98
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer (2013) 0.97
Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. ACS Chem Biol (2011) 0.97
Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis (2014) 0.97
Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol (2016) 0.95
Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther (2007) 0.93
Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene (2015) 0.92
Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochem Biophys Res Commun (2007) 0.91
Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorg Med Chem Lett (2013) 0.85
Niclosamide Analogs for Treatment of Ovarian Cancer. Int J Gynecol Cancer (2015) 0.82
Targeting SH2 domains in breast cancer. Future Med Chem (2014) 0.82
A flow cytometry technique to study intracellular signals NF-kappaB and STAT3 in peripheral blood mononuclear cells. BMC Mol Biol (2007) 0.81
[Molecular mechanisms of niclosamide antitumor activity]. Biomed Khim (2015) 0.77
Identification of Lead Compounds as Inhibitors of STAT3: Design, Synthesis and Bioactivity. Mol Inform (2015) 0.76